Splitomicin 是 NAD(+) 依赖性组蛋白去乙酰化酶 Sir2p 的特异性抑制剂，可抑制酵母提取物中 HDAC，IC50为 60 μM。

Splitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.

Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. [1] Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release. [2]

In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation. [3]

5690-03-9

C13H10O2

198.22

斯普利特麻一辛;1-Naphthalenepropanoic Acid

Ethanol:19.8 mg/mL (100 mM)
DMSO:19.8 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years